Gen Ilac ve Saglik Urunleri Sanayi ve Ticaret AS
IST:GENIL.E
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
111
216.9
|
| Price Target |
|
We'll email you a reminder when the closing price reaches TRY.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Operating Margin
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
Peer Comparison
| Country | Company | Market Cap |
Operating Margin |
||
|---|---|---|---|---|---|
| TR |
|
Gen Ilac ve Saglik Urunleri Sanayi ve Ticaret AS
IST:GENIL.E
|
41.7B TRY |
Loading...
|
|
| US |
|
Eli Lilly and Co
NYSE:LLY
|
1T USD |
Loading...
|
|
| UK |
D
|
Dechra Pharmaceuticals PLC
F:1PK
|
5.1B EUR |
Loading...
|
|
| US |
|
Johnson & Johnson
NYSE:JNJ
|
529.7B USD |
Loading...
|
|
| CH |
|
Roche Holding AG
SIX:ROG
|
275.3B CHF |
Loading...
|
|
| UK |
|
AstraZeneca PLC
LSE:AZN
|
210.3B GBP |
Loading...
|
|
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.8T DKK |
Loading...
|
|
| CH |
|
Novartis AG
SIX:NOVN
|
221.9B CHF |
Loading...
|
|
| US |
|
Merck & Co Inc
NYSE:MRK
|
269.1B USD |
Loading...
|
|
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
218B USD |
Loading...
|
|
| US |
|
Pfizer Inc
NYSE:PFE
|
145.8B USD |
Loading...
|
Market Distribution
| Min | -16 384.1% |
| 30th Percentile | 1% |
| Median | 6.4% |
| 70th Percentile | 15.5% |
| Max | 944% |
Other Profitability Ratios
Gen Ilac ve Saglik Urunleri Sanayi ve Ticaret AS
Glance View
Gen Ilaç ve Saglik Ürünleri Sanayi ve Ticaret AS operates as a supplier of orphan drugs. The firm operates in the fields of manufacturing all kinds of pharmaceuticals for human use and health products, trading, import and export. Gen Ilac manufactures products used in the treatment of rare diseases and disorders in neurology, endocrinology, nephrology, oncology, hematology and pediatric branches. The firm has approximately 500 employees working in its production facilities on a closed area of 15,000 square meters, established on an area of approximately 43,000 square meters in Ankara ASO 2nd and 3rd Organized Industrial Zone. Entity has 5 offices abroad: Germany, Russia, Kazakhstan, Uzbekistan and Azerbaijan.
See Also
Operating Margin is calculated by dividing the Operating Income by the Revenue.
The current Operating Margin for Gen Ilac ve Saglik Urunleri Sanayi ve Ticaret AS is 7.4%, which is below its 3-year median of 9.2%.
Over the last 3 years, Gen Ilac ve Saglik Urunleri Sanayi ve Ticaret AS’s Operating Margin has decreased from 11.8% to 7.4%. During this period, it reached a low of 6.5% on Jun 30, 2024 and a high of 14.4% on Mar 31, 2023.